

WHO Efforts to Enhance Access to Vaccine Supply

Seoul, DCVMN Annual Meeting

Tania Cernuschi, Vaccine Supply | Supply, Technologies, and Financing
Expanded Programme on Immunization (EPI) | Department of Immunization, Vaccines and Biologicals (IVB)

SUSTAINABLE FINANCING AND SUPPLY FOR IMMUNIZATION – WHO's work



1	Improving country regulatory environment	NRAs strengthening, streamlining of registration requirements, PQ programme
2	Guiding vaccine research and development	R&D Blueprint – priority pathogens & TPPs, position papers
3	Financing for vaccines and immunization	CMYPs, immunization financing assessments, monitoring of financial flows & advocacy
4	Strengthening national supply chain systems	EVMs, stock-out monitoring, Gavi supply chain strategy
5	Scaling up innovative products and thermostability	CTC, new delivery technologies & packaging
6	Stockpiling of vaccines for outbreak response	YF, cholera, meningitis, influenza, polio, smallpox
7	Information for access	Market intelligence for policy making & country support

WHO's work in context




Why are we engaging?



Global vaccine demand mapped






Source: Global Vaccine Market Model (GVMM) Demand Module, Linksbridge, SPC, Bill & Melinda Gates Foundation funded project, July 2017

Access to vaccines in MICs




Non Gavi MICs represent 50% of countries with declining DTP3 coverage (2010- 2016) and almost 40% PCV3 unimmunised

Infants not immunised with PCV3 (2016)



Drop in DTP3 Coverage – non-Gavi MICs



Source: WHO GVAP Report 2017 - WUENIC/JRF data

Member States have asked WHO to take action







Resolution 54.11 - WHA -May 2001

Ohi 5 Ohhal Varian Artist Plan

Obj. 5 Global Vaccine Action Plan -GVAP

SAGE Recommendation - MIC Strategy

Resolution 68.6 - WHA - May 2015

Resolution 69.25 - WHA - May 2016

SAGE Recommendation April 2015

27/09/2017 | Information for Access



What is the information gap and how can we close it?

NEED

Countries lack visibility into vaccine markets for decision making

Missing global view of vaccine market preventing risk management

Several countries cannot access sustainable & fair pricing

ENABLER

Identifying price ranges and supplier, product, procurement options

Complement existing information on vaccine markets from Gavi, UNICEF and PAHO RF

Completing understanding of global pricing dynamics

BENEFIT

Informed planning & procurement leading to sustainable demand



Informed risk identification & target actions to manage vaccine shortages



Informed dialogue on fair pricing




Information for Access in a nutshell



Collecting, analyzing and distributing price/procurement/ demand/supply data

Technical assistance to countries to access supply



Conducting in depth global market analysis for vaccines at risk


Designing strategies to enhance affordability

Guidelines/tools for country forecasting & procurement

Guiding supply and demand dynamics to address vaccine shortages



Global Vaccine Market Intelligence Hub



The Vaccine Price, Product, Procurement Initiative (V3P)



- 144 countries are participating in V3P by sharing procurement information
- Through V3P, we have visibility on vaccine prices for 84% world countries (95% of the world birth cohort)
- Reported data for 2016:
 - total value of \$7.8bn
 - total volume of 3.2bn
 - purchased from 73 manufacturers






Note: The graph represents all countries that have directly shared price data with V3P, regardless of the quality of the data.



Informed planning - aP & wP-containing vaccines

- MICs have been switching from wP-containing products to aPcontaining products
- Countries need to take into account the high difference in price between aP and wP

P Containing Vaccines – 2016 Reported Price









Informed procurement – a country example

	Product Supply		Product Demand		Product Prices							
Country example: UMIC43	Number of manufacturers (presentation sizes)		Frequency (%) of No. of countries countries using procuring the same product presentation		WAP price in USD (min-max)							
Vaccine / presentation	EUR	World	EUR (n=34)	World (n=142)	EUR	World	UMIC43	All UMICs EUR	Self-procuring UMICs worldwide	Pooled procurement UMICs worldwide	Self-procuring LMIC worldwide	Self-procuring UMIC worldwide larger presentation
BCG / 10d amp	8 Amp: 10, 20 Vial: 20	16 ; Amp: 5, 10, 20 ; Vial: 10, 20	26 (76%)	127 (89%)	10/25 (40%)	19/126 (15%)	0.06 (0.06-0.11)	0.11 (0.08 – 1.69)	0.50 (0.06 – 1.69	0.17 (0.14 – 0.26	0.06 (0.05 – 0.07)	1.05 (0.08 – 2.41)
HPV / 1d pfs	2 Vial: 1; pfs: 1	4 Vial: 1, 2; pfs: 1	13 (38%)	42 (29%)	12/12 (100%)	38/41 (93%)	75.91 (59.87– 113.30)	15.49 (15.00 - 22.41)	11.44 (7.38 – 22.41)	10.68 (3.74 - 15.00)	13.69	NA
Vaccine type Manufacturers reported by EUR countries				Manufacturers reported by countries worldwide								
BCG	BCG	BB-NCIPD; Biomed Lublin; GreenSignal Bio Pharma Limited; Intervax; Japan BCG Laboratory; Mikrogen; Serum Institute of India; Torlak Institute of Virology, Vaccines and Sera					AJ Vaccines A/S; BB-NCIPD; Biomed Lublin; China CNBG; FAP (Fundação Ataulpho de Paiva); GreenSignal Bio Pharma Limited; Institut Pasteur Iran; Institut Pasteur Tunis; Intervax; IVAC (Institute of Vaccines and Medical Biologicals); Japan BCG Laboratory; Mikrogen; PT Bio Farma (Persero); Serum Institute of India; Thai Red Cross Society; Torlak Institute of Virology, Vaccines and Sera					


VP


Source: V3P database (2016 data extract)

Overview of global vaccine market



Non-Gavi MICs represent ~40% of global vaccine market by volume and ~16% by value





Source: V3P&, Global Vaccine Market Model (GVMM), Linksbridge, SPC, Bill & Melinda Gates Foundation funded project, September 2017

27/09/2017 | Information for Access 13



Managing Vaccine shortages - BCG



■ MARKET UPDATE BCG VACCINE

Key Takeaways

- For 2017, BCG vaccine supply is estimated to be 1.5 times greater than forecasted demand. This excess supply is reassuring given the instability of the manufacturing process and is important progress from the restricted supply situation in recent years.
- However, demand flexibility is limited due to product registration constraints and supply is still concentrated, with a few large suppliers with prequalified products serving most countries. Consequently, shortages may still occur.

QUICK STATS

NUMBER OF PRODUCTS

1

TOTAL NUMBER OF SUPPLIERS

19

2017 ESTIMATED MAXIMUM GLOBAL SUPPLY

~500M doses

2017 FORECASTED GLOBAL DEMAND

~350M doses

2015 REPORTED PRICE RANGE

US \$0.04-\$15.08 (Median: \$0.52)


Source: WHO May 2017 - in collaboration with Linksbridge and MMGH Consulting



Informed dialogue on fair pricing

- There is a clear association between GNI per capita and price level
- We also observe larger price variation for higher income:
 - non-Gavi MICs, max price = 14x min
 - HICs, max price = 30x
 min
- We can improve transparency of pricing strategies and encourage fair pricing to strengthen access







Fair Pricing Forum






- A global dialogue to explore strategies for establishing fair prices that is sustainable for health systems and for innovation
- Participants: 250 participants from Member states, IGOs, NGOs, academia and industry
- Organized jointly by WHO and the Ministry of Health, Welfare and Sport of The Netherlands
- The Forum took take place in Amsterdam, the Netherlands on 10-11 May 2017
- For more information, please see
 http://www.fairpricingforum2017.nl/home

Source: WHO EMP

27/09/2017 Information for Access

The Humanitarian Mechanism





- WHO, UNICEF, MSF and Save the Children have launched the Humanitarian Mechanism in May 2017
- Aim: to facilitate timely access to affordable supply for entities such as Civil Society Organizations, Governments or UN Agencies who are procuring on behalf of populations facing humanitarian emergencies
- The mechanism currently covers access to PCV vaccines by CSOs and UN agencies from all available manufacturers at US\$ ~ 3 per dose
- Since launch, the mechanism has been used 6 times (+3 during pilot phase)
- WHO, UNICEF, MSF and Save the Children encourage all vaccine manufacturers to offer additional relevant products under the mechanism

27/09/2017 | Information for Access 18

Tools for countries



How do we support countries?



27/09/2017 | Information for Access 19





We are testing different tools to share information with countries

Country Fact Sheets

V3P: Country Fact Sheet

Products and Presentations

UMIC43 reported the purchase of 25 separate products in 2016, ranging from the most common (BCG) to the least common (D). Presentation sizes ranged from single-dose to 20-dose. Presentation types include ampoules (amp), vials, prefilled syringes (pfs), and an intranasal sprayer (I.N. sprayer). About half of all products purchased in UMIC43 (11/25) are in presentations that are either exclusive to UMIC43, or are used by very few other countries. For these products, prices are difficult to compare with other countries.

Procurement Method

UMIC43 is exclusively self-procuring, compared to 21 other exclusively selfprocuring countries, three mix procuring countries, and eight exclusively poolprocurement countries in the European Region (EUR) (procurement method for one country is unreported).

The Vaccine Market

The vaccine market in UMIC43 is approximately 5% of the overall EUR market by volume and about 3% by value, or about 0.3% and 0.1%, respectively, of the global market.

Vaccine Prices

For four key product groups, UMIC43 paid above the weighted average price (WAP) of other self-procuring UMICs in EUR in 2016:

Prices of DTaP combination vaccines (DTaP and DTaP-Hib-IPV) to UMIC43
are generally higher than average prices to other self-procuring UMICs in
EUR:



UMIC43

This country fact sheet is intended for use by MoH and vaccine procurement staff. The country fact sheet provides information on all vaccines procured by UMIC43 including:

- » an analysis of the most frequently reported vaccines to the V3P worldwide and in your WHO region;
- » a list of existing manufacturers for each of the products procured by UMIC43;
- » a list of available presentations for each of the products procured by UMIC43;
- » a list of prices paid by UMIC43, compared to the range of prices paid by other countries

Increased knowledge about several aspects of vaccine purchasing may aid in the decision-making for new vaccine introductions, budgeting, vaccine scheduling and product choice, and may inform procurement processes.

The Vaccine Product Price & Procurement (V3P) initiative was launched to provide all countries

Prices for Gavi Transitioning Countries

	PCV							
	Intro with Gavia	GSK 2-dose vial ^b	Pfizer 1-dose vial	Pfizer 4-dose vial				
Angola	✓	NE	\$3.30	\$3.10				
Armenia	✓	NE	\$3.30	\$3.10				
Azerbaijan	✓	NE	\$3.30	\$3.10				
Bhutan	Х	\$3.50/3.05°	\$3.30	NE				
Bolivia	✓	NE	\$3.30	\$3.10				
Congo, Rep	✓	NE	\$3.30	\$3.10				
Cuba	Χ	\$3.50/3.05 ^c	\$3.30	NE				
Georgia	✓	\$3.50/3.05	\$3.30	\$3.10				
Guyana	✓	NE	\$3.30	\$3.10				
Honduras	✓	NE	\$3.30	\$3.10				
Indonesia	Χ	\$3.50/3.05°	\$3.30	NE				
Kiribati	✓	NE	\$3.30	\$3.10				
Moldova	✓	NE	\$3.30	\$3.10				
Mongolia	✓	NE	\$3.30	\$3.10				
Nicaragua	✓	NE	\$3.30	\$3.10				
PNG	✓	NE	\$3.30	\$3.10				
Sri Lanka	Χ	\$3.50/3.05°	\$3.30	NE				
Timor-Leste	Χ	\$3.50/3.05°	\$3.30	NE				
Ukraine	Χ	NE	\$3.30	NE				
Uzbekistan	✓	NE	\$3.30	\$3.10				
Vietnam	Χ	\$3.50/3.05°	\$3.30	NE				

09/10/2017 | Title of the presentation 20

Engaging suppliers



How can we best work together?



How can we best work together?





- We regularly collect information from countries, UNICEF, PAHO RF on vaccine procurement
- We also collect information from suppliers on ad-hoc basis. Would manufacturers engage to share information more regularly? E.g. products, registration
- Would it be useful to also regularly collect demand forecasts from self-procuring countries?
- What other information would suppliers find useful to enhance access?
- How best to share information collected and results of analysis?
- What are the key efforts on supply and demand side that must accompany V3P?



Tania Cernuschi, Vaccine Supply Supply, Technologies, and Financing Expanded Programme on Immunization (EPI) Dept of Immunization, Vaccines and Biologicals cernuschit@who.int